Drug Discovery World

JULY 2, 2024

They developed the molecule, which went on to become Tracleer, a blockbuster drug for pulmonary arterial hypertension (PAH), and Actelion was subsequently acquired by Johnson & Johnson for $30 million. In 2005, Glycart was acquired by the Roche Group and integrated in Roche Pharma Research and Early Development (pRED).

Science 148

Science Drugs Clinical Trials Licensing 148

Agency IQ

FEBRUARY 12, 2024

BY RACHEL COE, MSC | FEB 7, 2024 10:21 PM CST The Bespoke Gene Therapy Consortium A collaborative effort, the Bespoke Gene Therapy Consortium (BGTC) was launched in October 2021 to “accelerate development of gene therapies for the 30 million Americans who suffer from a rare disease.”

FDA 40

FDA Therapies Clinical Trials Virus 40

Drug Target Review

JANUARY 8, 2024

Contrary to popular belief, ageing is not caused by just random wear and tear of our bodies over time but is instead caused by a discrete set of biological mechanisms that we now better understand and can target with therapies. a commercial stage pharmaceutical company. acquired by Teva Pharmaceuticals in 2014.

Science 145

Science Disease FDA Approval Pharmaceutical Companies 145

Vial

APRIL 10, 2024

The increasing costs associated with in-house drug development have prompted biotech and pharmaceutical companies to increasingly outsource to contract research organization s (CROs) for assistance. Vial’s track record includes over 750 completed trials and a network of more than 35 research sites.

Clinical Trials 52

Clinical Trials Trials Compliance Clinical Research 52

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. billion in funding. Northern Ireland “Northern Ireland is a medtech super-hub,” says Saleko.

Drugs 190

Drugs Science Therapies Targeted Protein Degradation 190

The Pharma Data

MARCH 23, 2023

The new Phase III clinical study, ARASTEP, will investigate the efficacy of darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline.

Trials 40

Trials Therapies Treatment Disease 40

The Pharma Data

JULY 8, 2021

The update includes an addition to the Indications and Usage section of the label (Section 1) to emphasize the disease stages studied in the clinical trials, as seen below ( italics to note updated language). Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).

Clinical Trials 52

Clinical Trials FDA Approval Trials FDA 52

The Pharma Data

JANUARY 14, 2021

(NASDAQ: FPRX) today announced clinical results from the global, randomized, double-blind placebo-controlled Phase 2 FIGHT trial evaluating first-in-class targeted therapy bemarituzumab in advanced gastric or gastroesophageal junction (GEJ) cancer. The ASCO GI presentation slides are available on the company’s website.

Trials 52

Trials Treatment Therapies Clinical Trials 52

The Pharma Data

JUNE 25, 2021

Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (A?) Breakthrough Therapy designation is an FDA program intended to expedite the development and review of medicines for serious or life-threatening conditions.

Disease 40

Disease Treatment Therapies FDA 40

The Pharma Data

NOVEMBER 23, 2020

At Ultimovacs, he will lead all business and corporate development efforts and continue to maintain and foster connections with leading biotechnology and pharmaceutical companies. “In For further information, please see www.ultimovacs.com. View source version on businesswire.com: [link].

Clinical Trials 52

Clinical Trials Small Molecule Pharmaceutical Companies Licensing 52

The Pharma Data

DECEMBER 31, 2020

where he led global clinical development programs including clinical strategy, clinical development, and regulatory affairs. He also previously served as Global CMO at Taiho Pharmaceutical Company, Ltd. Benedetti most recently served as chief medical officer for Apollomics, Inc.,

Engineering 52

Engineering Pharmaceuticals Virus Clinical Development 52

The Pharma Data

NOVEMBER 25, 2020

Under the agreement, which may generate revenue for BioInvent of up to SEK 30 million , BioInvent will provide process development, scale-up, supply of material for toxicological studies and clinical grade material in 1000L scale for use in phase I and II clinical trials.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

The Pharma Data

MARCH 15, 2022

Global Head of Research and Development for Sanofi “ The collaboration with Blackstone will accelerate our ability to offer patients a subcutaneous anti-CD38 antibody therapy that we believe will be innovative and more convenient. 2 prior therapies, including lenalidomide and a proteasome inhibitor. Nicholas Galakatos, Ph.D.

Science 52

Science Treatment Clinical Trials Therapies 52

Drug Discovery World

OCTOBER 18, 2022

This confluence of factors has created a true biopharma hub, with over 700 life science companies settling there since 2016 from various sectors, including biotechnology, digital health, medical technology, chemistry, nanotechnology, advanced manufacturing, and legal and financial consulting. Supporting pioneers in cancer research.

International 130

International Engineering Science Pharmaceuticals 130

Drug Discovery World

SEPTEMBER 16, 2022

Here, DDW Editor Reece Armstrong explores the global hubs of innovation for cell and gene therapies. Since the approval of Kymirah in 2017, the cell and gene therapy sector has emerged as an exciting and innovative market, representing some of the most promising drugs the pharmaceutical industry has ever seen. .

Therapies 130

Therapies Clinical Trials Production Trials 130

The Pharma Data

OCTOBER 19, 2020

19, 2020 — A recently approved rheumatoid arthritis medication appears to be an effective second-line therapy when biologic treatments start to fail, a new clinical trial reports. She is executive medical director of immunology clinical development for the pharmaceutical company AbbVie in North Chicago, Ill.

Clinical Trials 52

Clinical Trials Drugs Trials Treatment 52

The Pharma Data

JANUARY 6, 2021

With the IND approval, UNION is granted permission to advance oral orismilast into Phase 2b trials in humans with moderate to severe plaque psoriasis to evaluate the safety and efficacy of orismilast. We confidently believe in the benefits of oral orismilast, and the IND approval marks a significant milestone in our clinical development.”

FDA Approval 52

FDA Approval FDA Clinical Development Clinical Research 52

The Pharma Data

MARCH 7, 2022

Astellas”) today announced topline results from the Phase 3 SKYLIGHT 4™ clinical trial investigating the long-term safety of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause (VMS) which will support future regulatory filing submissions.

Treatment 52

Treatment Clinical Trials Trials Pharmaceutical Companies 52

The Pharma Data

JANUARY 27, 2021

Based on these results, we will now move to identify the recommended Phase II dose for the Phase IIa part of the trial and look forward to further evaluating the exciting potential of BI-1206 to bring much needed innovation to lymphoma patients,” said Martin Welschof, Ph.D, The Company’s validated, proprietary F.I.R.S.T

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

The Pharma Data

DECEMBER 8, 2020

BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively.

Clinical Trials 40

Clinical Trials Licensing Licensing International 40

The Pharma Data

MARCH 5, 2021

Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime Therapeutics for $38.00 About the FIGHT Trial.

Trials 52

Trials Therapies Clinical Development Pharmaceutical Companies 52

The Pharma Data

JANUARY 19, 2021

BioInvent’s management team will also give an update on the ongoing Phase I/IIa trial of BI-1206 in combination with rituximab and BioInvent’s partner CASI Pharmaceuticals (NASDAQ: CASI) will provide an update on the development plan and potential for BI-1206 in China.

Clinical Trials 40

Clinical Trials Licensing Licensing International 40

The Pharma Data

DECEMBER 8, 2020

With offices in the Netherlands, Germany and Singapore, the plan is to invest about 80% into European companies and the rest in North American startups. . Offering 23 million shares between $14-$17 apiece for a hopeful total of $391 million , the company is lining up the biggest debut on record for a Canadian biotech. Nuance Pharma

RNA 52

RNA Protein Expression Therapies Disease 52

The Pharma Data

JANUARY 3, 2021

03, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company traded on the Stock Exchange of Hong Kong (1477.HK),

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Licensing Licensing 52

The Pharma Data

JULY 29, 2021

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following 18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof of Concept Study at 2021 Alzheimer’s Association International Conference (AAIC) . Chief Clinical Officer, Neurology Business Group, Eisai. aggregates (protofibrils).

Clinical Trials 52

Clinical Trials Treatment Clinical Development Disease 52

The Pharma Data

NOVEMBER 30, 2020

The lead candidate, HTL0022562, has advanced through preclinical development demonstrating promising and differentiated properties for further investigation in human trials. We look forward to working on this new collaboration with Biohaven, a world leader in the clinical development of CGRP-targeted therapies.”

Small Molecule 40

Small Molecule Licensing Licensing Clinical Trials 40

The Pharma Data

SEPTEMBER 8, 2020

More specifically, the agency requires that scientific evidence for regulatory approval must come from large, high quality clinical trials that are randomized and observer-blinded, with an expectation of appropriately designed studies with significant numbers of participants across diverse populations. Follow us at @JNJNews.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 8, 2020

More specifically, the agency requires that scientific evidence for regulatory approval must come from large, high quality clinical trials that are randomized and observer-blinded, with an expectation of appropriately designed studies with significant numbers of participants across diverse populations. About AstraZeneca. AstraZeneca.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

JANUARY 14, 2021

. Pathophysiology of IgA nephropathy & Nefecon Clinical Biomarker Data. A Review of the Phase 3 NefIgArd Trial Data. Clinical Development – Pipeline Review. Clinical Development – Pipeline Review.

Clinical Trials 40

Clinical Trials Hospitals Disease International 40

Drug Discovery World

MARCH 6, 2024

Guiding neurological drug discovery and development to success The 20 years since the Human Genome Project has seen transformational advances in the molecular understanding of cancers and rare genetic diseases, leading to genetically informed, personalised selection of therapies and massively improved outcomes for many patients.

Clinical Trials 163

Clinical Trials Pharmaceutical Companies Disease Trials 163

The Pharma Data

NOVEMBER 26, 2020

BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

The Pharma Data

AUGUST 19, 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANT TM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations.

Treatment 52

Treatment FDA Approval Pharmacokinetics FDA 52

The Pharma Data

OCTOBER 14, 2020

14, 2020 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the U.S. and CHICAGO , Oct.

FDA Approval 52

FDA Approval FDA Treatment Pharmaceutical Companies 52

Drug Discovery World

AUGUST 8, 2022

DDW Editor Reece Armstrong speaks to Stephanie Seremetis, Chief Medical Officer, Rare Blood Disorders at Novo Nordisk to get her response to the company’s latest study results for its Mim8 antibody. Zero bleeds were reported in the eight participants treated with the therapy once monthly. . Could you elaborate on this?

Treatment 130

Treatment Clinical Trials International Disease 130

Drug Discovery World

OCTOBER 30, 2023

These biomarkers could potentially also be used to select patients most likely to benefit from a drug targeting a specific mechanism, so that smaller, faster, more targeted clinical trials can be designed. Crucially these patients are also well characterised clinically.

Treatment 183

Treatment Clinical Trials Disease Trials 183

The Pharma Data

DECEMBER 8, 2020

. “ TETON represents a significant move outside the pulmonary hypertension space, but based on data collected during the recent INCREASE study we’re confident that inhaled treprostinil can help address clinical gaps presented by existing therapies in IPF.” Forward-looking Statements.

FDA 40

FDA Treatment FDA Approval Drugs 40

The Pharma Data

MARCH 29, 2022

Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) today announce Boehringer Ingelheim’s selection of Veeva Development Cloud to drive end-to-end processes and seamless information sharing enterprise wide for greater speed in the delivery of innovative therapies. About Boehringer Ingelheim.

Therapies 52

Therapies Clinical Development Pharmaceutical Companies Research 52